32 terminated. 32 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Terminated 32 |
| Phase 2 | 8 | Terminated 8 |
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY4064912 in Healthy Participants and With Overweight or Obesity LY4064912, Placebo - Overweight or Obesity, Healthy | Phase 1 | Terminated | Eli Lilly and Company | 77 | 2025-08-28 | 2026-09-14 |
| Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity PF-07976016, PF-06882961 - Overweight, Obesity | Phase 1 | Terminated | Pfizer | 21 | 2025-03-13 | 2025-08-07 |
| Diazoxide Suppression Test P&F Study Diazoxide, 3 mg/kg per dose - Insulin Resistance, Hyperinsulinemia | Phase 1 | Terminated | Columbia University | 1 | 2024-10-23 | 2026-08-07 |
| A Phase 1b Study to Evaluate the Safety of XEN-101 XEN-101, Placebo - Obesity | Phase 1 | Terminated | Xeno Biosciences | 33 | 2024-05-24 | 2024-09-24 |
| A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 ZP7570, Placebo - Safety and Tolerability | Phase 1 | Terminated | Zealand Pharma | 84 | 2023-09-15 | 2025-04-25 |
| A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM ALN-KHK, Placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 1 / Phase 2 | Terminated | Alnylam Pharmaceuticals | 49 | 2023-03-10 | 2025-05-07 |
| A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range PF-07081532, Semaglutide - Obesity | Phase 1 | Terminated | Pfizer | 32 | 2023-01-19 | 2025-01-14 |
| ALY688-SR in Generally Healthy Overweight or Obese Adults ALY688-SR - Overweight and Obesity | Phase 1 | Terminated | Allysta Pharmaceutical | 8 | 2021-05-19 | 2021-08-30 |
| Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects Botox 200 UNT Injection - Obese, Diabetes Mellitus, Type 2 | Phase 1 / Phase 2 | Terminated | Vanderbilt University Medical Center | 4 | 2021-04-29 | 2023-02-28 |
| Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity AMG 171, Placebo - Obesity | Phase 1 | Terminated | Amgen | 60 | 2019-12-13 | 2024-09-19 |
| A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen) - Overweight, Obesity | Phase 1 | Terminated | Novo Nordisk A/S | 29 | 2019-07-15 | 2019-10-23 |
| A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis FT-4101, FT-4101 placebo, Deuterated Water - Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity | Phase 1 / Phase 2 | Terminated | Forma Therapeutics, Inc. | 14 | 2019-05-17 | 2025-10-20 |
| Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study Xenon - Obesity | Phase 1 | Terminated | University of North Carolina, Chapel Hill | 17 | 2015-09-01 | 2025-11-25 |
| Safety, Tolerability and Efficacy Study of PP1420 in HV PP1420, Placebo - Obesity | Phase 1 / Phase 2 | Terminated | Imperial College London | 49 | 2014-08-01 | 2021-09-22 |
| Multiple Dose Study Of PF-05231023 In Obese Adult Subjects Placebo, 100 mg PF-05231023 - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Terminated | Pfizer | 4 | 2013-09-01 | 2014-09-17 |
| Non-invasive Brain Modulation for Weight Maintenance Brain modulation, Sham modulation - Obesity | Phase 1 | Terminated | Massachusetts General Hospital | 13 | 2013-05-01 | 2016-10-31 |
| Study of TAP and Laparoscopic and Robotic Gynecologic Procedures and Obese Women Ropivacaine 0.5% 20cc injectate bilaterally, Placebo - Pain | Phase 1 / Phase 2 | Terminated | Montefiore Medical Center | 35 | 2013-04-01 | 2020-08-20 |
| Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects P7435 - Healthy, Overweight and/or Obese Subjects | Phase 1 | Terminated | Piramal Enterprises Limited | 32 | 2012-05-01 | 2013-07-09 |
| Peripheral Vasodilation in Obese Humans Drug Trial 1 (EDD), Drug Trial 2 (ROV) - Obesity | Phase 1 | Terminated | University of Wisconsin, Madison | 8 | 2012-04-16 | 2022-02-11 |
| Molecular Regulation of Muscle Glucose Metabolism U100 Humulin, Exercise - Obesity, Type 2 Diabetes Mellitus | Phase 1 | Terminated | Mayo Clinic | 48 | 2012-04-01 | 2017-11-27 |
Showing 20 of 32. Sign in to see all of them.
Obesity (30) · Diabetes Mellitus, Type 2 (7) · Insulin Resistance (4) · Nutrition Disorders (3) · Non-alcoholic Fatty Liver Disease (2) · Aneurysm (1) · Body Weight (1) · Diabetes Mellitus (1) · Dwarfism (1) · Dwarfism, Pituitary (1) · Fatty Liver (1) · Glucose Intolerance (1) · Hyperinsulinism (1) · Lipid Metabolism Disorders (1)
Nutritional and Metabolic Diseases (32) · Pathological Conditions, Signs and Symptoms (32) · Body Weight (31) · Overnutrition (31) · Signs and Symptoms (31) · Nutrition Disorders (29) · Metabolic Diseases (10) · Endocrine System Diseases (9) · Glucose Metabolism Disorders (9) · Diabetes Mellitus (7) · Hyperinsulinism (4) · Digestive System Diseases (2) · Liver Diseases (2) · Body Weight Changes (1)
semaglutide (2) · Anastrozole (1) · Botulinum Toxins, Type A (1) · Breakfast (1) · Corn Oil (1) · Diazoxide (1) · Exercise (1) · Goserelin (1) · Insulin (1) · Insulin, Regular, Human (1) · Omacor (1) · PF-05231023 (1) · Ropivacaine (1) · Sodium Chloride (1) · Testosterone (1)
Novo Nordisk A/S (3) · Pfizer (3) · Massachusetts General Hospital (2) · Allysta Pharmaceutical (1) · Alnylam Pharmaceuticals (1) · Amgen (1) · AstraZeneca (1) · Boston University (1) · Columbia University (1) · Eli Lilly and Company (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Forma Therapeutics, Inc. (1) · GlaxoSmithKline (1) · Imperial College London (1) · Indiana University (1)
United States (22) · United Kingdom (3) · Australia (2) · Germany (2) · India (2) · Brazil (1) · Canada (1) · Singapore (1)
Ben Snyder, MD (1) · Bruno Geloneze, MD, PhD (1) · Carine M Lenders, MD, MS, ScD (1) · Dr Dharmesh Domadia (1) · Dr Madhavi Latha Kodru (1) · Frances J Hayes, MD (1) · Ja Hyun Shin (1) · Jack A Yanovski, M.D. (1) · James Ritter, BM BCH, MRCP, FRCP (1)
PMID 19475464, PMID 22088584, PMID 25453088, PMID 41388232, PMID 42053447
2014 (1), 2018 (1), K23AT004251 (1), R01HL105820 (1)